MARKET

SAVA

SAVA

Cassava Sciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

69.53
-33.82
-32.72%
After Hours: 71.15 +1.62 +2.33% 19:59 07/30 EDT
OPEN
87.85
PREV CLOSE
103.35
HIGH
95.15
LOW
65.00
VOLUME
25.20M
TURNOVER
--
52 WEEK HIGH
146.16
52 WEEK LOW
2.780
MARKET CAP
2.78B
P/E (TTM)
-245.4289
1D
5D
1M
3M
1Y
5Y
S&P Rises More Than 2% in July
S&P Rises More Than 2% in July
Zacks · 12h ago
Midday Hot Stocks: CPRI, POWI rise on earnings; ERYP jumps on FDA designation; SAVA plunges
Earnings headlines continued to exert their influence in Friday's midday action. Capri Holdings (NYSE:CPRI) and Power Integrations (NASDAQ:POWI) both posted double-digit gains in intraday action, thanks to better-than-expected quarterly reports.
Seekingalpha · 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers
Benzinga · 1d ago
Midday Market Update: Why Are Stocks Down Today?
Investor Place · 1d ago
MRIN, BLIN, BAP among mid-day movers
Gainers: ERYTECH Pharma ERYP +64%. Allied Healthcare Products AHPI +49%. iFresh (NASDAQ:IFMK) +35%. Marin Software Incorporated (NASDAQ:MRIN) +29%. Atlassian Corporation TEAM +24%. Xiaobai Maimai (NASDAQ:HX) +18%. First High-School Education (NYSE:FHS) +16...
Seekingalpha · 1d ago
Unusual Options Activity Insight: Cassava Sciences
On Friday, shares of Cassava Sciences (NASDAQ:SAVA) saw unusual options activity. After the option alert, the stock price moved down to $90.72.
Benzinga · 1d ago
Cassava Sciences drag rivals lower amid concerns over its Alzheimer’s drug
A group of biotech companies focused on developing treatments for Alzheimer’s disease is trading lower in the pre-market continuing their losses on Thursday following updates to their development programs. Cassava
Seekingalpha · 1d ago
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SAVA. Analyze the recent business situations of Cassava Sciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SAVA stock price target is 148.00 with a high estimate of 215.00 and a low estimate of 100.00.
EPS
Institutional Holdings
Institutions: 141
Institutional Holdings: 12.40M
% Owned: 31.00%
Shares Outstanding: 40.01M
TypeInstitutionsShares
Increased
34
2.22M
New
58
1.09M
Decreased
29
1.20M
Sold Out
10
1.54M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Chairman/Director/President/Chief Executive Officer
Remi Barbier
Chief Financial Officer
Eric Schoen
Other/Director
Nadav Friedmann
Other
James Kupiec
Independent Director
Richard Barry
Independent Director
Robert Gussin
Independent Director
Michael O' Donnell
Independent Director
Sanford Robertson
Independent Director
Patrick Scannon
Declaration Date
Dividend Per Share
Ex-Div Date
12/07/2012
Dividend USD 0.75
12/13/2012
10/25/2010
Dividend USD 2
12/13/2010
  • All
  • Financials
  • Insiders
More
About SAVA
Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.

Webull offers kinds of Cassava Sciences Inc stock information, including NASDAQ:SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.